Asprey follows a strict diet without snacks
A 2025 PMC-published narrative review confirmed BPC-157's preclinical evidence in orthopaedic and sports medicine research, noting improvements in tendon healing and tendon-to-bone integration in animal models
What Patients Should Know: Current Evidence: Although BPC-157 has shown promising results in animal studies for healing stomach ulcers, improving gut barrier function, and reducing inflammation, there is a lack of well-designed clinical trials in humans
Gopal Grandhige, MD, FACS, Board-Certified Surgeon Last Reviewed: April 20, 2026 BPC-157 has a half-life of approximately 4 to 6 hours when administered via subcutaneous injection, so the peptide itself clears your system relatively quickly
Our review details the pros and cons